FindTrial
Sign In

A study to keep a systematic watch over the treatment of the children and adolescent patients diagnosed with Chronic Myeloid Leukemia (CML) (a type of blood cancer) and to modify the frequency of treatment for the same

Treatment and monitoring of children and adolescents with Chronic Myeloid Leukemia (CML)- A prospective observational study.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/11/029199
Enrollment
150
Registered
2020-11-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Dr Nirmalya Roy Moulik
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age 2) Diagnosis of CML (Ph-positive)

Exclusion criteria

Exclusion criteria: 1) Non-CML myeloproliferation

Design outcomes

Primary

MeasureTime frame
1)Monitor response to TKI s (1st and 2nd generation). 2)Prospectively monitor TKI toxicity (both short-term and long â??term). Timepoint: Every 3 Monthly OPD visit—

Secondary

MeasureTime frame
1)Ensure timely switch from 1st (imatinib) to 2nd generation TKI (nilotinib/dasatinib). 2)Offer to interrupt TKI in good responders who satisfy stopping criteria and closely monitor them for molecular recurrence and resumption of treatment in case of recurrence. Timepoint: Every 3 Monthly OPD visit—

Countries

India

Contacts

Public ContactDr Nirmalya Roy Moulik

Tata Memorial Hospital

roymoulik@gmail.com7045991385

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 5, 2026